Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03565536 | Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | completed | Phase 2 | 18 | Fujian Medical UniversityOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03470259 | Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging(TARGET) | completed | Phase 1 | 19 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06333587 | Minimally Invasive Treatments of the Thyroid(MIPA-MITT) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06325787 | Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma | completed | N/A | 1,021 | Chinese PLA General HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02592356 | Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | completed | N/A | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06286631 | Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale | recruiting | — | 800 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06277180 | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06271044 | a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS | active not recruiting | N/A | 61 | Helsinki University Central HospitalOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06243965 | Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?(DSR-MTC) | completed | — | 246 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05962892 | A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | — | 600 | Beijing Friendship HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | terminated | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05989555 | Effects of Radioactive Iodine on the Immune System in Thyroid Cancer(SCIMITAR) | unknown | — | 30 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05545852 | A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC | unknown | N/A | 290 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06079723 | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068101 | Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | completed | — | 274 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT01659385 | Leptin Levels in Papillary Thyroid Cancer(LL-PTC) | completed | — | 18 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02814032 | Proteomics of Papillary Thyroid Carcinoma | unknown | — | 32 | The Affiliated Hospital of Inner Mongolia Medical UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05932121 | Cross-sectional Case and Control Study on Quality of Life, Appearance and Functions in PTC Via Different Surgical Approach | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | enrolling by invitation | — | 6,750 | Novo Nordisk A/SINDUSTRY | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05873283 | Papillary Thyroid Cancer and Central Lymp Node Dissection | completed | — | 250 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | May 24, 2023 | clinicaltrials |
| NCT05819593 | Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05796960 | European Multicenter Study on Surgical Management of Advanced Thyroid Cancer(ATCEU) | unknown | — | 3,917 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04922801 | Optimising Molecular Radionuclide Therapy(SELFIE) | completed | — | 50 | King's College LondonOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02773667 | Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine(RETENTION) | completed | — | 83 | Jena University HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05178186 | Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer(THYCOVID) | completed | N/A | 22,974 | University of CagliariOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | terminated | Phase 2 | 4 | Emory UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03432299 | Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma(RFAforPTMC) | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01236547 | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2024source: clinicaltrials